FY2025 · ended Dec 31, 2025 · Revenue $427.54M, +40.0% YoY · Filed Feb 23, 2026
GeneDx Holdings Corp. (WGS) files with the SEC under industry code 8000, Services-Health Services. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $427.5 million and a net loss of $21.0 million. Free cash flow was $14.3 million. As of Jun 30, 2026 it held $132.5 million in cash and investments and $100.0 million in total debt.
Revenue (TTM)
$454.43M
+25.4% vs year-ago TTM
Net income (TTM)
$-106.36M
-7664.5% vs year-ago TTM
Operating cash flow (TTM)
$-48.71M
-474.0% vs year-ago TTM
Free cash flow (TTM)
$-75.80M
-9232.3% vs year-ago TTM
EPS (TTM)
$-3.72
-7649.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
29.29M
+4.3% vs prior year
Net cash
$32.55M
as of Jun 30, 2026
Operating margin
-20.3%
FY 2026
Company profile
- Industry
- Services-Health Services (SIC 8000)
- Listed as
- WGS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Stamford, CT
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1818331
- Former names
- Sema4 Holdings Corp. (until Jan 5, 2023); CM Life Sciences, Inc. (until Jul 21, 2021)
Other Services-Health Services companies
- LifeStance Health Group, Inc. LFST
- Privia Health Group, Inc. PRVA
- Pennant Group, Inc. PNTG
- U S Physical Therapy Inc /NV USPH
- InnovAge Holding Corp. INNV
- Omada Health, Inc. OMDA
- P3 Health Partners Inc. PIII
- Alps Group Inc ALPS
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $427.5M | $305.4M | $202.6M | $234.7M | $212.2M |
| Operating income | -$13.1M | -$23.2M | -$180.6M | -$667.7M | -$446.1M |
| Net income | -$21.0M | -$52.3M | -$175.8M | -$549.0M | -$245.4M |
| Diluted EPS | -$0.73 | -$1.94 | -$7.23 | -$53.63 | -$2.27 |
| Operating cash flow | $33.3M | -$28.5M | -$180.1M | -$319.2M | -$190.4M |
| Free cash flow | $14.3M | -$34.0M | -$185.4M | -$326.3M | -$199.8M |
| Total assets | $523.7M | $419.4M | $418.8M | $490.9M | $554.1M |
| Total liabilities | $215.5M | $174.1M | $190.7M | $237.2M | $166.0M |
| Stockholders' equity | $308.2M | $245.2M | $228.0M | $253.7M | $388.1M |
| Cash and investments | $171.3M | $141.2M | $130.1M | $123.9M | $400.6M |
| Total debt | $115.0M | $120.0M | $122.8M | $77.1M | $11.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 16, 2026 | Jun 15, 2026 |
| 10-Q | Quarterly report | May 4, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 4, 2026 | May 4, 2026 |
All 781 GeneDx Holdings Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.